The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer
dc.contributor.author | Beer, Tomasz M. | en_US |
dc.contributor.author | Tangen, Catherine M. | en_US |
dc.contributor.author | Bland, Lisa B. | en_US |
dc.contributor.author | Hussain, Maha H. A. | en_US |
dc.contributor.author | Goldman, Bryan H. | en_US |
dc.contributor.author | DeLoughery, Thomas G. | en_US |
dc.contributor.author | Crawford, E. David | en_US |
dc.date.accessioned | 2007-09-18T19:18:23Z | |
dc.date.available | 2007-09-18T19:18:23Z | |
dc.date.issued | 2006-08-01 | en_US |
dc.identifier.citation | Beer, Tomasz M.; Tangen, Catherine M.; Bland, Lisa B.; Hussain, Maha; Goldman, Bryan H.; DeLoughery, Thomas G.; Crawford, E. David (2006). "The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer." Cancer 107(3): 489-496. <http://hdl.handle.net/2027.42/55777> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55777 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16804926&dopt=citation | en_US |
dc.description.abstract | BACKGROUND. The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial. METHODS. The multivariate associations between 3-month change in HGB and baseline characteristics were evaluated with a linear regression model. The associations between 3-month change in HGB level and time-to-event outcomes, including overall survival and progression-free survival, were evaluated by using proportional hazards regression models. RESULTS. Quartiles of baseline HGB levels were ≤12.0 g/dL, from 12.1 to 13.7 g/dL, from 13.8 to 14.7 g/dL, and >14.7 g/dL. Overall, 3 months after initiating ADT, the mean HGB level declined 0.54 g/dL (standard deviation [SD], 1.68 g/dL); however, the mean HGB level increased by 0.99 g/dL (SD, 1.83 g/dL) in patients who had baseline HGB levels <12 g/dL and decreased 1.04 g/dL (SD, 1.28 g/dL) in patients who had baseline HGB levels ≥12 g/dL. After adjusting for potential confounders, including baseline HGB level, a decline in HGB after 3 months of ADT was associated independently with shorter survival (hazards ratio [HR], 1.10 per 1 g/dL decline; P = .0035) and shorter progression-free survival (HR, 1.08 per 1 g/dL decline; P = .013). An unexpected finding was that the effect of baseline HGB on overall and progression-free survival varied significantly by race. CONCLUSIONS. In a sample of men with newly diagnosed, metastatic prostate cancer, a decline in HGB level after 3 months of ADT was associated with shorter survival and progression-free survival after adjusting for disease status and other baseline covariates. Although race alone was not a strong predictor of death or disease progression, the effect of the baseline HGB level on overall and progression-free survival varied significantly by race. Cancer 2006. © 2006 American Cancer Society. | en_US |
dc.format.extent | 145307 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, Washington ; Southwest Oncology Group (SWOG-8894), Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217 | en_US |
dc.contributor.affiliationother | Department of Surgery, Division of Urology, Oregon Health and Science University, Portland, Oregon | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, Washington | en_US |
dc.contributor.affiliationother | Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon | en_US |
dc.contributor.affiliationother | Department of Urology, Division of Oncology, University of Colorado Health Science Center, Denver, Colorado | en_US |
dc.identifier.pmid | 16804926 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55777/1/22029_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.22029 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.